ReviewClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2005
Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance.
Review in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 126 citations in OpenAlex.
- Clinical and Ecological Impact of an Educational Program to Optimize Antibiotic Treatments in Nursing Homes (PROA-SENIOR): A Cluster, Randomized, Controlled Trial and Interrupted Time-Series Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Association between a carbapenem post-prescription audit and gram-negative susceptibility: a 6-year time-series analysis.Archives of microbiology · 2026Article
- Spectrum, dose, and duration of antibiotic exposure and risk of intensive care unit-acquired carbapenem-resistant gram-negative bacteria: a prospective cohort study.Annals of intensive care · 2025Article
- Analysis of ESAC-Net/EARS-Net Data from 29 EEA Countries for Spatiotemporal Associations Between Antimicrobial Use and Resistance-Implications for Antimicrobial Stewardship?Antibiotics (Basel, Switzerland) · 2025Article
- Review
- Antimicrobial Stewardship Program (ASP) in General Hospital: An Essential Practice.Antibiotics (Basel, Switzerland) · 2024Article
- Long-Term Clinical and Ecological Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Utilizing co-abundances of antimicrobial resistance genes to identify potential co-selection in the resistome.Microbiology spectrum · 2024Article
- Leveraging Large Data, Statistics, and Machine Learning to Predict the Emergence of ResistantPharmacy (Basel, Switzerland) · 2024Article
- Chestnut Honey Is Effective against Mixed Biofilms at Different Stages of Maturity.Antibiotics (Basel, Switzerland) · 2024Article
- Biofilms in wound healing: A bibliometric and visualised study.International wound journal · 2023Article
- Impact of an empiric antimicrobial therapy manual on antimicrobial usage and multidrug resistant organism trends in a large Italian teaching hospital.Infection prevention in practice · 2022Article
- Assessment of preauthorization and 24-hour expert consultation as a restrictive antimicrobial stewardship bundle in a Brazilian tertiary-care hospital: an interrupted time series analysis.Infection prevention in practice · 2022Article
- Impact of cascade reporting of antimicrobial susceptibility on fluoroquinolone and meropenem consumption at a Veterans' Affairs medical center.Infection control and hospital epidemiology · 2022Article
- Prevalence and Patterns of Antimicrobial Resistance amongVeterinary sciences · 2021Article
- Change-points in antibiotic consumption in the community, European Union/European Economic Area, 1997-2017.The Journal of antimicrobial chemotherapy · 2021Review
- Characterization of the antibacterial activity from ethanolic extracts of the botanical, Larrea tridentata.BMC complementary medicine and therapies · 2021Article
- Evolution of the Gram-Negative Antibiotic Resistance Spiral over Time: A Time-Series Analysis.Antibiotics (Basel, Switzerland) · 2021Article
- Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem Resistant Gram-Negative Bacilli: An Interrupted Time-Series Analysis.Antibiotics (Basel, Switzerland) · 2021Article
- The Use of Colistin in Food-Producing Animals in Estonia-Vaccination as an Effective Alternative to Consumption of Critically Important Antimicrobials in Pigs.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing problem of emerging antimicrobial resistance has been likened to a balloon where settling one specific issue results in a 'bulge' of even worse problems. However, much has been learned about how to best use our critical antibacterial agents in ways to avoid or even repair some of the resistance damage that has been done. A compilation of current literature strongly suggests that to slow the development of resistance to antimicrobial agents it is optimal to use drugs with more than one mechanism of action or target, to prescribe those with demonstrated ability to minimise or reverse resistance problems, and to avoid underdosing of potent antibiotics. The most recent information also indicates that it is best to limit empirical use of beta-lactam plus fluoroquinolone combination therapy, since these two classes activate some common resistance responses, and using them together can facilitate multidrug resistance in important pathogens, particularly Pseudomonas aeruginosa and Acinetobacter species. This review discusses the role of each major antimicrobial class on resistance development and presents specific strategies for combating the growing problem of multidrug-resistant bacteria. We now have the knowledge to better manage our antimicrobial agent prescribing practices, but finding the will and resources to apply our understanding remains a formidable challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.